Description
Key facts
Cell type:RAW 264.7,
Species or organism:Mouse,
Tissue:Lymphatic,
Knockout validation:Sanger Sequencing,
Mutation description:Knockout achieved by using CRISPR/Cas9, Homozygous: 74 bp deletion in exon 3,
Disease:Carcinoma
Product details:
Knockout cell lysate achieved by CRISPR/Cas9.
REACH authorisation
Abcam has not and does not intend to apply for the REACH Authorisation of customers' uses of products that contain European Authorisation list (Annex XIV) substances.
It is the responsibility of our customers to check the necessity of application of REACH Authorisation, and any other relevant authorisations, for their intended uses.
Lysate preparation:
Our lysates are made using RIPA buffer to which we add a protease inhibitor cocktail and phosphatase inhibitor cocktail (ratio: 300:100:10).
This means that the protein of interest is denatured.
If you require a native form of the protein please use the live cell version. Please refer to our lysis protocol for further details on how our lysates are prepared.
User storage instructions:
Lyophilizate may be stored at 4°C. After reconstitution, store at -20°C for short-term storage or -80°C for long-term storage.
This product is subject to limited use licenses from The Broad Institute and ERS Genomics Limited, and is developed with patented technology. For full details of the limited use licenses and relevant patents please refer to our
limited use license
patent pages
Properties and Storage Information:
Gene name-CCR2, Gene editing type-Knockout, Gene editing method-CRISPR technology, Knockout validation-Sanger Sequencing, Zygosity-Homozygous, Shipped at conditions-Ambient - Can Ship with Ice, Appropriate short-term storage conditions--20°C, Appropriate long-term storage conditions--20°C
Supplementary Information:
This supplementary information is collated from multiple sources and compiled automatically.
CCR2 also known as C-C chemokine receptor type 2 is a protein involved in immune cell trafficking. It is a member of the G-protein-coupled receptor family and has a molecular mass of approximately 43 kDa. CCR2 is primarily expressed on monocytes dendritic cells and certain subsets of T cells. It functions as a receptor for monocyte chemoattractant proteins (MCPs) with MCP-1 (CCL2) being the most well-known ligand. The interaction between CCR2 and its ligands directs the movement of these immune cells to sites of inflammation or tissue injury.
Biological function summary
CCR2 plays an important role in mediating leukocyte migration. It acts in the immune system to guide monocytes from the bloodstream into tissues contributing to immune surveillance and response. CCR2 operates not as part of a larger receptor complex but it does interact closely with other chemokine receptors which may influence its signaling. The receptor's activity has critical implications for inflammatory processes and lies at the heart of many immune responses.
Pathways
CCR2 is integrally involved in the chemokine signaling pathway and the inflammatory response pathway. Its function in these pathways highlights its role in modulating immune cell infiltration during immune challenges. The receptor also interfaces with other important signaling proteins such as CCR5 which like CCR2 is another chemokine receptor involved in mediating immune cell movement. These interactions overlap and complement each other offering nuanced regulation of immune cell dynamics.
CCR2 has connections to conditions such as atherosclerosis and rheumatoid arthritis. In atherosclerosis the receptor's involvement in monocyte recruitment to the arterial wall is an important step in plaque formation. Its role in rheumatoid arthritis centers on the promotion of leukocyte infiltration into the joint tissues contributing to inflammation and joint damage. CCR2's connection to such disorders often aligns with a similar role played by other chemokine receptors like CCR5 highlighting its relevance in inflammation-related pathologies.
